MSI-L
About
Biomarker Type: Microsatellite Stability
Present: True
Status: Microsatellite instability-low (MSI-L)
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | MSI-L | Endometrial Carcinoma | Lenvatinib, Pembrolizumab |